Improved telangiectasia and reduced recurrence rate of rosacea after treatment with 540 nm‑wavelength intense pulsed light: A prospective randomized controlled trial with a 2‑year follow‑up

Luo,Yang; Luan,Xiu‑Li; Zhang,Jian‑Hong; Wu,Lan‑Xi; Zhou,Nan

doi:10.3892/etm.2020.8617

Improved telangiectasia and reduced recurrence rate of rosacea after treatment with 540 nm‑wavelength intense pulsed light: A prospective randomized controlled trial with a 2‑year follow‑up

Authors:
- Yang Luo
- Xiu‑Li Luan
- Jian‑Hong Zhang
- Lan‑Xi Wu
- Nan Zhou
View Affiliations

Affiliations: Department of Dermatology, The 940th Hospital of Joint Logistics Support Force of Chinese People's Liberation Army, Lanzhou, Gansu 730050, P.R. China
Published online on: March 20, 2020 https://doi.org/10.3892/etm.2020.8617
Pages: 3543-3550
Copyright: © Luo et al. This is an open access article distributed under the terms of Creative Commons Attribution License.

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

The aim of the present study was to evaluate the clinical efficacy and safety of 540 nm-wavelength intense pulsed light (IPL) for the treatment of telangiectasia in late‑stage rosacea. Between July 2013 and January 2016, patients with rosacea who tested positive for Demodex folliculorum were recruited. Patients received anti‑mite therapy and were then randomly apportioned to receive either three 540 nm‑IPL treatments at 4‑week intervals (IPL group), or no treatment (control group). Telangiectasia was assessed by the same clinician at baseline and at follow‑up intervals over 2 years, where ≥90% clearance of telangiectasia was considered to indicate effective treatment. The rates of effective treatment, improvement (≥30% clearance) and recurrence (original or neo‑location) were compared in both groups. After 33 patients were lost during follow‑up, the IPL and control groups were comprised of 107 and 120 patients for the final analysis, respectively. The rates of effective treatment and total efficacy in the IPL group (66.36 and 95.33%, respectively) were found to be significantly higher compared with those of the control group (0 and 30.83%, respectively). By contrast, the rates of recurrence were found to be lower in the IPL group (8.41%) compared with the control group (48.33%). Redness‑to‑blisters associated with IPL treatment (9.7% of analyzed patients) subsided within one week and hyperpigmentation (1.9%) within 3 months. To conclude, treatment with 540 nm‑IPL improved facial telangiectasia in late‑stage rosacea that remained after sequential anti‑mite therapy and effectively reduced the recurrence of rosacea. The present study was registered into the Chinese Clinical Trial Registry under the title ‘Sequential therapy for mites folliculitis’ (Trial registration number: ChiCTR‑IPR‑15006451; approved May 27, 2015).

View Figures

View References

1	Wilkin J, Dahl M, Detmar M, Drake L, Liang MH, Odom R and Powell F: National Rosacea Society Expert C. Standard grading system for rosacea: Report of the National Rosacea Society Expert Committee on the classification and staging of rosacea. J Am Acad Dermatol. 50:907–912. 2004.PubMed/NCBI View Article : Google Scholar
2	Crawford GH, Pelle MT and James WD: Rosacea: I. Etiology, pathogenesis, and subtype classification. J Am Acad Dermatol. 51:327–341; quiz 342-324. 2004.PubMed/NCBI View Article : Google Scholar
3	Wacker T and Lang GK: Demodex folliculorum: Diagnosis and therapy today. Klin Monbl Augenheilkd (German). 231:241–245. 2014.PubMed/NCBI View Article : Google Scholar
4	Alinia H, Tuchayi SM, James SM, Cardwell LA, Nanda S, Bahrami N, Awosika O, Richardson I, Huang KE and Feldman SR: Measurement of disease severity in a population of rosacea patients. Dermatol Clin. 36:97–102. 2018.PubMed/NCBI View Article : Google Scholar
5	Oussedik E, Bourcier M and Tan J: Psychosocial burden and other impacts of rosacea on patients' quality of life. Dermatol Clin. 36:103–113. 2018.PubMed/NCBI View Article : Google Scholar
6	Egeberg A, Hansen PR, Gislason GH and Thyssen JP: Patients with rosacea have increased risk of dementia. Ann Neurol. 79:921–928. 2016.PubMed/NCBI View Article : Google Scholar
7	Faris C, Manjaly JG, Ismail-Koch H and Caldera S: Rapid treatment of rhinophyma with powered microdebrider. Case Rep Otolaryngol. 2013(621639)2013.PubMed/NCBI View Article : Google Scholar
8	Egeberg A, Hansen PR, Gislason GH and Thyssen JP: Patients with rosacea have increased risk of depression and anxiety disorders: A danish nationwide cohort study. Dermatology. 232:208–213. 2016.PubMed/NCBI View Article : Google Scholar
9	Gallo RL, Granstein RD, Kang S, Mannis M, Steinhoff M, Tan J and Thiboutot D: Standard classification and pathophysiology of rosacea: The 2017 update by the National Rosacea Society Expert Committee. J Am Acad Dermatol. 78:148–155. 2018.PubMed/NCBI View Article : Google Scholar
10	Micali G, Dall'Oglio F, Verzi AE, Luppino I, Bhatt K and Lacarrubba F: Treatment of erythemato-telangiectatic rosacea with brimonidine alone or combined with vascular laser based on preliminary instrumental evaluation of the vascular component. Lasers Med Sci. 33:1397–1400. 2018.PubMed/NCBI View Article : Google Scholar
11	Kennedy Carney C, Cantrell W and Elewski BE: Rosacea: A review of current topical, systemic and light-based therapies. G Ital Dermatol Venereol. 144:673–688. 2009.PubMed/NCBI
12	Del Rosso JQ, Tanghetti EA, Baldwin HE, Rodriguez DA and Ferrusi IL: The burden of illness of erythematotelangiectatic rosacea and papulopustular rosacea: Findings from a web-based survey. J Clin Aesthet Dermatol. 10:17–31. 2017.PubMed/NCBI
13	Luo Y, Sun YJ, Zhang L and Luan XL: Treatment of mites folliculitis with an ornidazole-based sequential therapy: A randomized trial. Medicine (Baltimore). 95(e4173)2016.PubMed/NCBI View Article : Google Scholar
14	Luo Y, Luan XL, Sun YJ, Zhang L and Zhang JH: Effect of recombinant bovine basic fibroblast growth factor gel on repair of rosacea skin lesions: A randomized, single-blind and vehicle-controlled study. Exp Ther Med. 17:2725–2733. 2019.PubMed/NCBI View Article : Google Scholar
15	Anzengruber F, Czernielewski J, Conrad C, Feldmeyer L, Yawalkar N, Hausermann P, Cozzio A, Mainetti C, Goldblum D, Goldblum D, et al: Swiss S1 guideline for the treatment of rosacea. J Eur Acad Dermatol Venereol. 31:1775–1791. 2017.PubMed/NCBI View Article : Google Scholar
16	Lowe E and Lim S: Paradoxical erythema reaction of long-term topical brimonidine gel for the treatment of facial erythema of rosacea. J Drugs Dermatol. 15:763–765. 2016.PubMed/NCBI
17	Husain Z and Alster TS: The role of lasers and intense pulsed light technology in dermatology. Clin Cosmetic and Invest Dermatol. 9:29–40. 2016.PubMed/NCBI View Article : Google Scholar
18	Tanghetti EA, Jackson JM, Belasco KT, Friedrichs A, Hougier F, Johnson SM, Kerdel FA, Palceski D, Hong HC, Hinek A and Cadena MJ: Optimizing the use of topical brimonidine in rosacea management: Panel recommendations. J Drugs Dermatol. 14:33–40. 2015.PubMed/NCBI
19	Gao L, Gao N, Song W, Dang E, Yin R, Wang L and Wang G: A retrospective study on efficacy of pulsed dye laser and intense pulsed light for the treatment of facial telangiectasia. J Drugs Dermatol. 16:1112–1116. 2017.PubMed/NCBI
20	Jansen T: Clinical presentations and classification of rosacea. Ann Dermatol Venereol. 138:S192–S200. 2011.PubMed/NCBI View Article : Google Scholar
21	Jansen T: Clinical presentations and classification of rosacea. Ann Dermatol Venereol. 138 (Suppl):S138–S147. 2011.PubMed/NCBI View Article : Google Scholar
22	Fitzpatrick TB: The validity and practicality of sun-reactive skin types I through VI. Arch Dermatol. 124:869–871. 1988.PubMed/NCBI View Article : Google Scholar
23	Goldberg DJ: Current trends in intense pulsed light. J Clin Aesthet Dermatol. 5:45–53. 2012.PubMed/NCBI
24	Dummer R, Graf P, Greif C and Burg G: Treatment of vascular lesions using the VersaPulse variable pulse width frequency doubled neodymium: YAG laser. Dermatology. 197:158–161. 1998.PubMed/NCBI View Article : Google Scholar
25	Wilkin J, Dahl M, Detmar M, Drake L, Feinstein A, Odom R and Powell F: Standard classification of rosacea. National Rosacea Society Expert Committee: Report of the National Rosacea Society Expert Committee on the classification and staging of Rosacea. J Am Acad Dermatol. 46:584–587. 2002.PubMed/NCBI View Article : Google Scholar
26	Xu Z, Tan X, Ye J, Zhang C, Zhao M and Zhan F: Evaluation of measles catch-up immunization campaign in Hubei, 2010. Chin J Viral Dis. 1:208–211. 2011.
27	Cribier B: Pathophysiology of rosacea: Redness, telangiectasia, and rosacea. Ann Dermatol Venereol. 138 (Suppl):S184–S191. 2011.PubMed/NCBI View Article : Google Scholar
28	Agnoletti AF, DEC E, Parodi A, Schiavetti I, Savarino V, Rebora A, Paolino S, Cozzani E and Drago F: Etiopathogenesis of rosacea: A prospective study with a three-year follow-up. G Ital Dermatol Venereol. 152:418–423. 2017.PubMed/NCBI View Article : Google Scholar
29	Forton FM: Papulopustular rosacea, skin immunity and Demodex: Pityriasis folliculorum as a missing link. J Eur Acad Dermatol Venereol. 26:19–28. 2012.PubMed/NCBI View Article : Google Scholar
30	Turgut Erdemir A, Gurel MS, Koku Aksu AE, Falay T, Inan Yuksel E and Sarikaya E: Demodex mites in acne rosacea: Reflectance confocal microscopic study. Australas J Dermatol. 58:e26–e30. 2017.PubMed/NCBI View Article : Google Scholar
31	Abokwidir M and Feldman SR: Rosacea management. Skin Appendage Disord. 2:26–34. 2016.PubMed/NCBI View Article : Google Scholar
32	Campolmi P, Bonan P, Cannarozzo G, Bruscino N, Troiano M, Prignano F and Lotti T: Intense pulsed light in the treatment of non-aesthetic facial and neck vascular lesions: Report of 85 cases. J Eur Acad Dermatol Venereol. 25:68–73. 2011.PubMed/NCBI View Article : Google Scholar
33	Liu J, Liu J, Ren Y, Li B and Lu S: Comparative efficacy of intense pulsed light for different erythema associated with rosacea. J Cosmet Laser Ther. 16:324–327. 2014.PubMed/NCBI View Article : Google Scholar
34	Wong WR, Shyu WL, Tsai JW, Hsu KH, Lee HY and Pang JHS: Intense pulsed light modulates the expressions of MMP-2, MMP-14 and TIMP-2 in skin dermal fibroblasts cultured within contracted collagen lattices. J Dermatol Sci. 51:70–73. 2008.PubMed/NCBI View Article : Google Scholar
35	Vigo L, Giannaccare G, Sebastiani S, Pellegrini M and Carones F: Intense pulsed light for the treatment of dry eye owing to meibomian gland dysfunction. J Vis Exp. 146:2019.PubMed/NCBI View Article : Google Scholar
36	Rainer BM, Kang S and Chien AL: Rosacea: Epidemiology, pathogenesis, and treatment. Dermatoendocrinol. 9(e1361574)2017.PubMed/NCBI View Article : Google Scholar
37	Lim HS, Lee SC, Won YH and Lee JB: The efficacy of intense pulsed light for treating erythematotelangiectatic rosacea is related to severity and age. Ann Dermatol. 26:491–495. 2014.PubMed/NCBI View Article : Google Scholar
38	Babilas P, Schreml S, Szeimies RM and Landthaler M: Intense pulsed light (IPL): A review. Lasers Surg Med. 42:93–104. 2010.PubMed/NCBI View Article : Google Scholar
39	Kawana S, Ochiai H and Tachihara R: Objective evaluation of the effect of intense pulsed light on rosacea and solar lentigines by spectrophotometric analysis of skin color. Dermatol Surg. 33:449–454. 2007.PubMed/NCBI View Article : Google Scholar